Payer PolicyActive
Flow Cytometry - (0538)
CIGNA-0538
Cigna
Effective: October 15, 2025
Updated: December 6, 2025
created · Dec 2, 2025
Policy Summary
Flow cytometry is covered as medically necessary for evaluation of hematopoietic/hematologic cancers, immunodeficiency disorders (including HIV/AIDS), paroxysmal nocturnal hemoglobinuria, gestational trophoblastic disease, and transplant-related indications, but is not covered for all other indications (including DNA ploidy/proliferation assessment in solid tumors). Claims must use appropriate covered diagnosis and current CPT/ICD procedure codes to be reimbursable and may be reviewed or denied by medical directors based on benefit terms and clinical judgment.
Coverage Criteria Preview
Key requirements from the full policy
"Flow cytometry is considered medically necessary for the evaluation of any of the following: Hematopoietic/hematologic cancers; Immunodeficiency disorders, including human immunodeficiency virus (H..."
Sign up to see full coverage criteria, indications, and limitations.